AstraZeneca’s rare disease unit Alexion closed a deal this week with Neurimmune for exclusive access to the latter’s investigational human monoclonal antibody NI006.

The antibody is a transthyretin amyloidosis depleter that could potentially treat patients with transthyretin amyloid cardiomyopathy, an under-recognized cause of heart failure in older adults.

Under the terms of the deal, Alexion will develop, manufacture and commercialize NI006 globally, paying Neurimmune $30 million upfront and potentially another $730 million in milestone payments as well as royalties on sales.